Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
1期
已完成
NCT00591214
| 适应症 | Chronic Hepatitis C |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Tanabe Pharma Corporation |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 10 人 |
|---|
| 干预（药物） | MP-424 (Telaprevir) |
|---|
| 开始日期 | 2007年12月 |
|---|
| 完成日期 | 2008年10月 |
|---|
| 结果公布日 | 2012年10月22日 |
|---|
摘要
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
Cmax (Maximum Observed Concentration in Plasma) of MP-424
Date were collected at Day1 to Day85 · μg / mL
| MP-424 | 2.24 ± 0.93 μg / mL |
|---|
| MP-424 | 3.34 ± 1.11 μg / mL |
|---|
| MP-424 | 3.68 ± 1.29 μg / mL |
|---|
Tmax (Time of Maximum Plasma Concentration) of MP-424
Date were collected at Day1 to Day85 · hours
| MP-424 | 2.50 hours |
|---|
| MP-424 | 2.49 hours |
|---|
| MP-424 | 2.72 hours |
|---|
AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424
Date were collected at Day1 to Day85 · μg x h /mL
| MP-424 | 11.60 ± 4.74 μg x h /mL |
|---|
| MP-424 | 22.31 ± 8.29 μg x h /mL |
|---|
| MP-424 | 23.98 ± 9.45 μg x h /mL |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。